40 results on '"El‐Agnaf, Omar"'
Search Results
2. Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up
3. Immune-related biomarkers for Parkinson's disease
4. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils
5. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease
6. Corrigendum to “ Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy Body Disease” [Neurobiology of Disease127 (2019) 163–177]
7. Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit
8. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology
9. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function
10. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils
11. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro
12. α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer
13. Retraction Notice to: Corrigendum to “Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson’s Disease and Other Brain Disorders”
14. Retraction Notice to: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson’s Disease and Other Brain Disorders
15. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease
16. α-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells
17. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
18. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease
19. The immune system in Parkinson's disease: From biology to diagnosis and therapeutic targets
20. Hydrogen Peroxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia
21. Assemblies of Alzheimer’s peptides Aβ25–35 and Aβ31–35: reverse-turn conformation and side-chain interactions revealed by X-ray diffraction
22. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease1,2
23. RETRACTED: Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
24. Fluorescence Anisotropy: A Method for Early Detection of Alzheimer β-Peptide (Aβ) Aggregation
25. New evidence that the Alzheimer β-amyloid peptide does not spontaneously form free radicals: An ESR study using a series of spin-traps
26. α-synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro
27. Oligomerization and Toxicity of β-Amyloid-42 Implicated in Alzheimer's Disease
28. Review: Formation and Properties of Amyloid-like Fibrils Derived from α-Synuclein and Related Proteins
29. RETRACTED: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders
30. HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α-SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH
31. ALPHA-SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES
32. STANDARDIZATION OF PRE-ANALYTICAL PROCEDURES FOR COLLECTION AND STORAGE OF CSF FOR THE MEASUREMENT OF NEUROGRANIN TRUNC P75 AND A-SYNUCLEIN
33. PERFORMANCE EVALUATION OF NEW ABSORBANCE-BASED ELISAS FOR MEASURING DIFFERENT ALPHA-SYNUCLEIN (A-SYN) SPECIES IN CSF AND PLASMA
34. Quantification of CSF and blood alpha-synuclein as a diagnostic marker for synucleinopathies
35. P4-326 Soluble aggregates of the peptide Adan induce apoptosis in neuronal cells
36. O3-04-05 A possible role for the formation of hydrogen peroxide during the early stages of protein aggregation in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders
37. O2-06-03 A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders
38. Sensitive detection of β-amyloid aggregation by means of time-resolved fluorescence polarisation anisotropy
39. Conformation and toxicity of the ABRI peptide in familial British dementia
40. Development of an ELISA to quantitate soluble oligomers of Aß
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.